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ABSTRACT
Antiestrogens (AE) are powerful biological tools used to
elucidate the molecular mechanisms of estrogen (E) action.
Tamoxifen (TAM) is a well known AE that is the treatment of
choice for E receptor positive mammary cancer. Despite its
reputation as an antagonist, estrogenic effects of TAM, such
as the induction of uterine growth in female mice and the
potentiation of aggression in intact male mice also have
been noted. The present study examined the effect of TAM on
two estrogen regulated processes, the activation of lordotic
behavior and the induction of progestin receptors (PR) in
the hypothalamic-preoptic area (HPOA) in female mice. The
effects of TAM, in the dosage range 0.5 - 100 ~g, were
studied with and without the presence of 5 ~g estradiol
benzoate (EB) to address the possibility of agonist and
antagonist effects. None of the TAM treatments activated
lordosis or induced PR in the HPOA. TAM antagonized EB-
activated lordosis in a dose dependent fashion, but did not
totally suppress lordosis even at the highest dose.
However, all doses of TAM suppressed EB-induced PR levels to
those seen in oil-treated mice. Differences noted in the
manner in which rats responded to TAM for the same responses
indicated a species-specific response to TAM.
Interestingly, variability in the action of TAM exists in
mice as indicated by its ability to potentiate aggression in
males yet block lordosis and PR induction in females. Due
1
to the sexually dimorphic nature of the neural substrates
for these responses, it was postulated that the early
hormonal environment may organize the eventual response to
TAM. One possible mechanism is the hormonal regulation of
chromatin organization Which governs the availability of DNA
sequences to which the receptor must bind to regulate gene
transcription. Another possibility explored is the variable
action of transcriptional activating factors located on the
estrogen receptor and tlie degree of synergism with species-,
tissue- and cell-specific transcription factors.
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CHAPTER ONE
INTRODUCTION
In broad terms, the aim of behavioral endocrinology is
to explain hormonal influences on behavior. To this end,
hormonally regulated behavior patterns that can be reliably
elicited and quantified serve as models. Hormonal
conditions are manipulated to determine the effects on the
behavior in question. One of the most thoroughly studied
sexual responses is lordosis, a reflex exhibited by a
sexually receptive female rodent upon being mounted by a
male. This response is characterized by a concave arching
of the back, elevating both the head and the rump, exposing
the genitalia (see Figure 1), and it is recognized as a
primary indicator of sexual receptivity.
Hormonal Regulation of Sexual Receptivity
Copulation in female rodents is dependent upon the
lordosis response; unless the female displays this posture,
intromission and ejaculation by the male are not possible
(Diakow, 1974; Pfaff, Diakow, Montgomery, & Jenkins, 1978).
The display of lordosis is dependent upon ovarian hormones
estrogen (E) and progesterone (P). Ovariectomized rodents,
whose endogenous source of E and P was removed, do not
exhibit the lordosis response (Boiling & Blandau, 1939).
Upon replacing E and P in physiological doses, the lordosis
response can be restored (Edwards, Whalen, & Nadler 1968;
Whalen, 1974). This method of removing the endogenous
3
Figure 1. Lordosis posture of the rat. Reprinted from S. A.
Barnett, The Rat: A study in Behavior, Chicago, 1963.
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source of hormones by castration and replacing the hormones
exogenously became known as the castration-replacement
paradigm. It was soon discovered that lordosis could be
brought about in ovariectomized rats (Davidson, Rodgers,
Smith, & Bloch, 1968; Edwards et al., 1968), hamsters
(Carter, Michael, & Morris, 1976), guinea pigs (Young, 1969)
and mice (Ring, 1944) solely by high doses of E (100~g).
This discovery led to the distinction between the priming
and the activational effects of E. When a physiological
dose of E is administered 24-48 h prior to P administration
and lordosis results, we speak of the ability of E to prime
the neural substrate for sexual receptivity. Without prior
administration of E, P cannot bring about sexual
receptivity. However, when higher doses of E (100 ~g) are
administered without P, the lordosis response can be
elicited. In this case we speak of the activational effects
of E. This is an important distinction that is necessary
for the elucidation of the neural mechanisms regulating
sexual behavior because in vivo, this behavior is regulated
by both E and P. Therefore, to understand the induction of
sexual receptivity, the hormonal conditions utilized must
reflect those that naturally occur.
Neural Substrates that Mediate
Sexual Receptivity
A great deal of research has sought to determine the
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brain sites mediating the effects of E and P on sexual
receptivity. Autoradiographic studies, in which tritiated
hormones such as E are injected systemically, enabled the
identification of brain regions that selectively retained E.
A number of E-concentrating sites in the hypothalamus,
medial preoptic area, amygdala, and pituitary of both mice
and rats were identified (Pfaff, 1968: Pfaff & Keiner, 1973:
Stumpf & Sar, 1975). Implant studies, which are a refined
version of the castration-replacement paradigm in which
minute amounts of crystalline steroids are directed to
particular brain regions, enabled experimenters to pinpoint
the location of behaviorally active cell groups. This led
to the identification of the ventromedial hypothalamus (VMH)
as the most effective site for E implants to activate sexual
receptivity in rats in the absence of P administration
(Barfield & Chen, 1977: Dorner, 1968: Lisk, 1962). Recall,
however, that in vivo both E and P regulate sexual behavior.
In order to mimic the natural circumstances in which E
primes the neural substrate for lordosis dilute implants of
E were utilized in other studies. When dilute implants of E
were directed to the ventromedial nucleus of the
hypothalamus (VMN), priming, but not activation of sexual
receptivity reSUlted, while implants in other areas such as
the preoptic area (POA) were virtually without effect
(Davis, McEwen, & Pfaff, 1979; Rubin & Barfield, 1980). A
combination of the implant and autoradiographic techniques
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enabled experimenters to determine that the degree of
diffusion of hormones from the implant sites was minimal
(within O.5mm) , thus more firmly establishing these sites as
behaviorally effective (Davis, Krieger, Barfield, McEwen, &
Pfaff, 1982). Additional evidence for the role of the VMN
in lordosis came from lesion studies in which the VMN or its
efferent (outgoing) pathways were destroyed, resulting in
abolished or severely disrupted sexual responsiveness
(Malsbury, strull, & Daood, 1978; Matthews, & Edwards,
1977). In addition, anisomycin, a protein synthesis
inhibitor, and tamoxifen, an antiestrogen, blocked the
facilitation of E and P activated lordosis when implanted
into the VMN, but not in the POA or interpeduncular region
(Glaser & Barfield, 1984; Rainbow, McGinnis, Davis, &
McEwen, 1982).
utilizing similar experimental methods the site of
action of P also was examined. Autoradiography indicated
that p-concentrating sites were localized to the
hypothalamus, preoptic area, amygdala, midbrain, and cortex
in a number of species (Blaustein & Feder, 1979; Kato &
Onuchi, 1977; Moguilewsky & Raynaud, 1977; Warembourg,
1978). utilizing doses of E sufficient to prime but not
activate lordosis, the effect of P implants in a number of
locations was examined. Only implants in or immediately
adjacent to the v}lli were behaviorally effective (Rubin, &
Barfield 1983a,b). This is interesting in view of several
7
reports that P implants in the midbrain stimulated lordosis
in E-primed rats (Luttge & Hughes, 1976: Ross, Claybaugh, ~
Clemens, Gorski, 1971: Yansae & Gorski, 1976). However, the
midbrain and the hypothalamus respond differently to E
priming. Estradiol treatments increased the concentration
of progestin receptors (PR) in the hypothalamus but not the
amygdala, cortex or midbrain of rats and guinea pigs
(Blaustein & Feder, 1979: MacLusky & McEwen, 1978, 1980:
Moguilewsky & Raynaud, 1979). While PR induction is not
sufficient for the activation of sexual receptivity, it has
been correlated with the appearance of this behavior
(further treatment of this issue is beyond the scope of the
present discussion: for reviews see Barfield, Glaser, Rubin
& Etgen, 1984: Etgen, 1984).
Hormone Receptors: Mechanism of Action
and Binding Characteristics
Another area of research which has received
considerable attention in the past two decades is the
biochemical mechanism of hormone action. The currently
accepted mechanism of hormone action is depicted in Figure
2. Hormones such as E and P diffuse across the cell
membrane where they bind to a receptor located in the
nuclear compartment (King & Green, 1984: Welshons & Gorski,
1988). Receptors possess the following binding
characteristics: (i) steroid specificity, only hormones of
the same class compete effectively for binding their
8
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Figure 2. Mechanism of hormone action.
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receptor. For example, androgens, will not compete with
radiolabeled estrogen ([3H]E) for E receptor (ER) binding,
whereas diethylstilbestrol (DES), a synthetic estrogen will
compete with [3 H]E for ER; (ii) tissue-specificity,
receptors are present in significantly greater amounts in
target tissues compared to nontarget tissues; (iii) high
affinity, because blood levels of hormones are usually 10-10
- 10-8 M, if the tissue is to respond to the hormone via a
receptor mechanism, the receptor must have an affinity for
the hormone which is in the range of the blood levels; (iv)
saturability, because the biological response to a hormone
is saturable, there must be a finite number of binding sites
for the hormone; (v) correlation with biological response,
it must be demonstrated that binding of the hormone by its
receptor results in a biological response (for review see
Clark & Peck, 1977). Upon binding hormone, the receptor
undergoes a ligand-induced conformational change termed
activation, which enables the receptor to bind with high
affinity to nuclear acceptor sites on specific genes and
alter ribonucleic acid (RNA) and protein synthesis (Rories &
Spelsberg, 1989; Thrall, Webster, & Spelsberg, 1978).
These findings on biochemical mechanisms were important
for behavioral research because it is this alteration in
gene expression that is thought to underlie the hormonal
regUlation of behaviors such as lordosis. Evidence that the
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activation of lordosis requires protein synthetic steps
comes from studies that utilized protein synthesis
inhibitors, such as anisomycin. When anisomycin was
administered systemically (Rainbow, Davis, & McEwen, 1980)
or implanted into the VMN (Glaser & Barfield, 1984; Rainbow,
McGinnis, Davis, & McEwen, 1982) it blocked the facilitation
of lordosis by E and P in ovariectomized rats.
In addition to protein synthesis inhibitors, other
~
chemicals have been utilized to determine the role of E and
P in the regulation of sexual receptivity. Among these are
E agonists and antagonists. An E agonist is a substance
that mimics the effects of Ei it works in a manner similar
to E to control gene regulation. An E antagonist or an
antiestrogen (AE) is a substance capable of blocking the
effects of estrogen.
Action of Tamoxifen in peripheral
and Neural Tissue
Antiestrogens are powerful biological tools that can be
used to elucidate the mechanism of estrogen action at the
molecular level~Tamoxifen (2-[4-(1,2-diphenyl-l-
butenyl)phenoxy]-N~~.dimethylethanamine-- TAM), is a
synthetic AE that is used primarily for the treatment of
estrogen receptor-positive breast cancer. TAM inhibits the
proliferation of E receptor-containing breast cancer cells,
as well as E-stimulated protein synthetic activities
including the induction of PR (Freiss, Prebois, Rocheforte,
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& Vignon, 1990; Katzenellenbogen, Miller, Mullick, & Sheen,
1985). competition for the estrogen receptor is widely
accepted as the mode of antagonistic action of TAM (Horwitz
& McGuire, 1978; Katzenellenbogen, Bhakoo, Ferguson, Lan,
Tatee, Tsai, & Katzenellenbogen, 1979). This is evident
since the sensitivity of different breast cancer cell lines
to the growth suppression effects of TAM is correlated with
their ER content. The growth of MCF-7 breast cancer cells,
which possesses a high concentration of ER, is inhibited
markedly by TAM, whereas the growth of T47D cells, which
possess relatively fewer ER, is inhibited only minimally
(Katzenellenbogen, et al., 1985).
Similar to other antiestrogens, TAM has been classified
as a mixed agonist-antagonist due to its ability to
facilitate, as well as block, estrogen-dependent responses
in a number of cell types and a variety of species (see
Pasqualini, sumida, & Giambiagi, 1988 for review). When
administered to ovariectomized rats in combination with
estradiol benzoate (EB) TAM antagonizes EB-induced
progesterone receptors (PR) in the uterus (Castellano-Diaz,
Gonzalez-Quijano, Liminana & Diaz-Chico, 1989; Kirchhoff,
GrUnke, Hoffmann, Nagel, Ghraf, 1983), the pituitary
(Kirchhoff et aI, 1983) and the hypothalamic preoptic area
(HPOA) (Etgen & Shamamian, 1986). Antagonism in rats has
also been reported for the activation of lordotic behavior
(Etgen & Sharnarnian, 1986), and the induction of uterine
12
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growth (Harper & Walpole, 1967). In the absence of
estrogenic stimulation, however, partial agonism is evident
in the increased concentration of PR in the uterus
(Castellano-Diaz et al., 1989; Kirchhoff et al., 1983),
pituitary (Kirchhoff et aI, 1983) and HPOA (Etgen &
Shamamian, 1986) as well as increased uterine weight (Harper
& Walpole, 1967). In addition, TAM is estrogenic in its
ability to induce synthesis of uterine complement component
C3, produced in the luminal and glandular epithelial cells
of the rat uterus (Sundstrom, Komm, Xu, Boundy, Lyttle,
1990) .
Variability of the effects of TAM is evident when one
reviews research utilizing the guinea pig. In both the
fetal and the neonatal guinea pig, TAM is as uterotrophic as
E. Further, when administered with E present, TAM does not
block but potentiates estrogen's effects (Pasqualini,
Sumida, Giambiagi, & Nguyen, 1987). However, TAM is not
purely an agonist for the guinea pig uterus. TAM alone has
no stimulatory effect on histone acetylation, whereas
estrogen stimulates acetylation 10-fold. Hhen TAM is co-
administered with E, antagonism of histone acetylation
results (Pasqualini, Cosquer-Clavreul, & Gelly, 1983). For
PR induction, TAM is only a partial E agonist in the fetal
uterus of the guinea pig, but a full agonist in the neonatal
uterus (Pasqualini et al., 1987). As in the uterus, TA}l is
as trophic as E in both the fetal and neonatal vagina, but
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unlike the uterus regarding the induction of PR, TAM is
only a partial agonist for both fetal and neonatal guinea
pigs (Nguyen, Giambiagi, Mayrand, Lecerf, & Pasqualini,
1986) .
The literature regarding the effects of TAM in mice is
both sparse and inconsistent depending on the response under
consideration. The controversy over its antagonist effects
in mice began in 1971 when Terenius reported that TAM was as
uterotrophic as estrogen in the mouse and that it did not
block estrogen-induced uterine growth. There has been a
recent report of the antiuterotrophic effects of TAM in the
dosage range of 0.001 - 100 ~g (Pavlik, van Nagell, Nelson,
Gallion, Donaldson, Kenady, & Barankowska-Kortylewicz,
1986). In this dosage range, TAM + EB (0.05 ~g) treated
mice exhibited only slight suppression of uterine weight,
220 - 300% of the noninjected controls compared to EB-
treated mice whose uterine weight was 300% of the
noninjected control. PR induction of the TAM + EB-treated
mice was 350 - 450% of noninjected control versus 450%
noninjected control for EB-treated mice. An alternate
interpretation might classify this as a partial agonist
effect.
Another area where agonist properties of TAM have been
reported is the potentiation of estrogen-activated
aggression in intact male mice (Simon & Perry, 1988).
Intact T~I-treated males (dosage range of 50.0 - 400.0 ~g
14
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TAM) had a signific~ntlY greater number of attacks against
stimulus males compared to oil-treated males. There were no
significant dose effects. Due to aromatization of
testosterone to E, intact males have an endogenous source of
E. One would expect TAM to decrease aggressive behavior
based on its action as an antiestrogen, through competition
for ER binding. However, TAM potentiated aggression above
the level seen in oil-treated intact males, thus apparently
acting as an E agonist.
It therefore seems reasonable to conclude that the
effect of TAM seems to be a function of the species, target
tissue and response under consideration, and that further
experimentation is needed to provide additional information
on the action of TAM. In this study, the effect of TAM on
two estrogen-regulated processes, the activation of lordotic
behavior and the induction of PR in the HPOA were examined
using CFW female mice as a model. The effects of TAM on
these processes were studied with and without the presence
of EB to address the possibility of agonist and antagonist
effects. Although a direct examination of the mechanism of
action of TAM was beyond the scope of these studies, it was
hoped that the data obtained would aid in developing
hypotheses concerning the mo~ecular events that mediate the
agonist/antagonist actions of TAM in the CNS of the female
mouse.
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CHAPTER TWO
METHODS
Animals
Sexually inexperienced female CFW mice (70-75 days of
age) purchased from the Charles River Breeding Farm
(Wilmington, MA) were housed in groupsQof four in 28 X 28 X
13-cm polycarbonate cages lined with wood chips until
treatments were initiated. They were maintained on a 12:12
hr reversed light/dark cycle with lights on at 1900 hr with
food and water available at all times. Mice were
bilaterally ovariectomized two weeks prior to use. They
were anesthetized with an intraperitoneal injection of
Nembutal supplemented with the inhalation anesthetic
Metofane. Surgery involved a 2 rom incision along the
lateral sides of the spinal cord posterior to the last rib.
After the ovaries were located and removed the peritoneum
was sutured shut and the incision closed with a wound clip.
All maintenance procedures were in compliance with Federal
guidelines for animal care. Ten mice were assigned to each
treatment group.
Treatments
Estradiol benzoate (EB) and progesterone (P) were
purchased from Steraloids (Wilton, NH), and TAM was
purchased from Sigma (St. Louis, MO). In Experiment One,
the females were randomly divided among the following
treatments: (i)TAH: either 0.5, 2.5, 5.0, 10.0 or 100.0 ~g;
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(ii) EB: 5.0 ~g; (iii) oil: vehicle only. Forty-two hours
after the administration of these treatments, each female
received a 500 ~g P injection. In Experiment Two, females
were given a combined treatment consisting of 5.0 ~g EB with
either 5.0, 10.0, or 100.0 ~g TAM, followed by 500 ~g P as
above. All treatments were administered subcutaneously in
0.02 cc oil vehicle between 1500-1600 hr (8-9 hr into the
dark cycle) and continued once a week for 4 weeks.
Behavioral studies
Measurement of lordotic behavior was conducted 6 hours
after P administfation between 1500-1900 hr, 8-12 hr into
the dark cycle under dim red illumination. Each test
consisted of placing females individually into a clear
polyethylene cage, 51 x 41 x 22 em, lined with wood chips, 5
minutes prior to introduction of a stud male mouse. The
stud males were given access to fully receptive females
prior to sessions with the experimental females. All
females were tested until they received 10 mounts or 30
minutes of exposure to the stud male. A lordosis quotient
(LQ), calculated as the percentage of mounts resulting in a
lordosis response, was used a measure of sexual receptivity.
Tests were conducted once a week for 4 weeks.
Progestin Receptor Assay
The week following the final behavioral test mice from
each group received TAM, EB, TAM+EB or oil injections 42 h
prior to sacrifice by cervical dislocation. Their brains
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removed rapidly and blocked on ice. The HPOA was removed as
a single block. The section was bordered posteriorly by the
mammillary bodies, laterally by the hypothalamic sUlci, and
anteriorly by a cut approximately 2 ~anterior to the optic
chiasm to a depth of approximately 2mm.
Subsequent steps were performed at 0-4°C. Tissue was
homogenized in 500 ~l of fresh ice-cold TEDGM buffer (10roM
Tris HC1, 1.5 roM EDTA, 1.5 roM dithiothreitol, 20% glycerol
(v/v) , 10mM sodium molybdate, pH=7.4 at 0° C) by 20 strokes
in a glass-teflon homogenizer followed by a 500 ~l wash and
8 additional strokes. The homogenate and wash were combined
and centrifuged for 10 minutes at 2000 x g in a fixed angle
rotor in an lEe Centra 7R centrifuge. The supernatant was
centrifuged for 60 min at 100,000 x g using an SW50.1 rotor
in a Beckman L8-70 Ultracentrifuge. The supernatant was
immediately used in the assay.
Incubations were conducted in 12 X 75 mm glass tubes
that were pretreated with 0.1% BSA prior to use. The
incubate consisted of 200 ~l of cytosol, 40 ~l of 0.4 nM
[3 H]R5020 (New England Nuclear, Boston MA; S.A. 84.7
Ci/mmol) and 10 ~l of buffer without (for measuring total
binding) or with (to assess non-specific binding) 100x
excess of unlabeled R5020. Samples were thoroughly mixed
and incubated at 0° C for 8 hr.
The incubation was terminated by the addition of 250 ~l
of hydroxylapatite (HAP) suspension (50% (v/v) HAP, 50%
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(v/v) TE buffer; pH=7.4 at O·C) into the incubation tubes.
The tubes were immediately vortexed at moderate speed for 10
seconds and this step was repeated every 10 minutes for 30
minutes. The incubates were then centrifuged for 4 minutes
at 1000 x g in a swinging bucket rotor. The supernatant was
aspirated, and the HAP pellet washed 4X in 2 ml of TE
containing 1% Tween 80 (polyoxyethylenesorbitan monooelate;
pH=7.4). Each wash was followed by a 3 minute
centrifugation at 1000 X g.
After the. final wash the walls of the tubes were
cleaned with ethanol and dried with cotton swabs. The
washed pellets were extracted in 1 ml of ethanol with
periodic vortexing and then centrifuged for 3 minutes at
1000 x g. A 900 ~l aliquot was taken and placed in a 20 ml
scintillation vial. The volume of ethanol was brought back
to 1 ml and the procedure was repeated again. Ten ml of
toluene based scintillation fluor was added and the samples
were counted in a Beckman LS-8100 liquid scintillation
counter. Efficency was determined by the external standard
channels ratio method.
Specifically bound hormone was calculated by
SUbtracting nonspecific from total binding. Protein
content was measured using the Bio-Rad Dye-Binding Reagent
Kit and all data were normalized by converting to a per mg
protein basis.
0.37 - 0.45 mg.
Protein values for the incubates ranged from
19
Data Analyses
The sexual behavior of the female mice was highly
variable in the EB + P group over the first two weeks of
testing and was stable over weeks 3 and 4. On this basis,
analyses of the behavioral data were based only on the last
two tests for all groups. In addition, data from fema~es
that were mounted less than 10 times during the course of a
behavioral test were excluded from the analysis for that
test to ensure that all females that had an equal
opportunity to express the behavior under study.
Biochemical data were analyzed by examining the relative
induction of PR in the experimental groups in comparison to
that seen in females that received EB + P and then EB alone
the week of the assay.
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CHAPTER THREE
RESULTS
Experiment 1: Does Tamoxifen Act
As An Estrogen Agonist?
Figure 3A shows the mean LQ's for each of the groups.
It is evident from this figure that only the EB + P
treatment led to the display of sexual receptivity. Mice in
this condition had a mean LQ of 59.7. None of the TAM + P
or oil + P treated mice were sexually responsive; the mean
LQ's for these groups ranged from 0 to 4.5.
Figure 4A shows the effect of the treatments on the
induction of PR in the HPOA. Data from the experimental
groups are presented as the percentage PR concentration
measured in EB-treated mice which was 371.17 DPM/mg. Only
the EB + P -treated mice exhibited significant induction of
PR. The induction of PR in TAM-treated mice ranged from
3.2% to 7.0% of the EB-treated controls. These
concentrations were similar to the basal levels of PR seen
in the oil-treated mice (7.4% of EB-treated mice). The
biochemical data is consistent with the behavioral data;
only EB + P treated mice showed significant PR induction and
were sexually responsive, whereas none of the TAM + P
treatments led to the induction of PR or the activation of
lordosis.
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Experiment 2: Does Tamoxifen Act
As An Estrogen Antagonist?
Figure 3B shows the mean LQ for TAM/EB + P treated
mice. An unweighted means ANOVA for linear trend revealed a
significant effect of TAM dosage (F (1,23) = 4.88, P <
0.05). The 5.0 ~g TAM dose did not suppress the ability of
EB + P to induce lordosis. The mean LQ for this group,
56.9, is similar to that of the mice that received only EB +
P (59.7). However, as the dose of TAM was increased to 10.0
~g and 100.0 ~g, mean LQs were suppressed to 41 and 20,
respectively.
Figure 4B depicts the effect of TAM, on the induction of
PR by EB. All three TAM treatments suppressed [3 H]R5020
binding in comparison to that seen in the EB + P group, and
there were no dose-related differences in this effect.
EB/TAM treated mice exhibited only basal levels of PR
induction (5.1 - 6.5% EB-treated mice) similar to the oil
treated mice (7.4% EB-treated mice).
22
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Figure 3.Effects of TAM alone (panel A) or TAM administered
concurrently with simultaneous 5 ~g EB (panel C) on
lordosis. EB- and oil- treated mice (panel B) served as
positive and negative controls, respectively.
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Figure 4. Effects of TAM alone (panel A) or TAM administered
concurrently with simultaneous 5 ~g EB (panel C) on HPOA
progestin receptor content. EB- and Oil- treated mice
(panel B) served as positive and negative controls,
respectively. Data are expressed relative to EB-treated
controls.
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CHAPTER FOUR
CONSIDERATION OF RESULTS
The results from the first experiment indicate that
TAM, in the dosages utilized in this study, did not act as a
CNS agonist for the activation of lordotic behavior and the
induction of PR in female mice. The latter finding differs
from that reported with rats (Etgen & Shamammian, 1986),
where a dissociation between the activation of lordosis and
the induction of PR occurred. More specifically, rats
administered 2.0 mg TAM 48 or 72 hr prior to sacrifice
exhibited approximately a 150% and 200% increase in PR
concentration respectively, in comparison to noninjected
controls. However, neither of these groups were sexually
responsive. This lack of sexual receptivity despite high
levels of PR induction has been reported elsewhere for rats
(Parsons, MacLusky, Krieger, McEwen, & Pfaff, 1979).
In the second experiment TAM blocked EB+P-activated
lordosis in a dose dependent fashion. This is in accord
with data obtained utilizing rats both when TAM was
administered peripherally, or intracranially (Etgen, 1979;
Howard, Etgen, & Barfield, 1984). Although no suppression
occurred with equimolar doses of TAM and EB (LQ = 56.9), as
the dose of TAM increased the degree of suppression
increased. Interestingly, the biochemical response was more
sensitive to the antagonist properties of TAM than the
behavioral response; all TAM/EB treatments suppressed PR
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induction to levels similar to oil-treated mice, while none
of these treatments were able to totally suppress lordosis.
The dissociation occurred most notably at the 5 ~g TAM dose
where behavior was unaffected despite the total suppression
of EB-induced PR. Similarly, at the 10.0 and 100.0 ~g TAM
doses behavior was still evident, though suppressed, despite
the lack of EB-induced PR. A similar dissociation of
behavioral and biochemical effects of TAM has been reported
for rats (Etgen, 1984; Etgen & Shammamian, 1986), where
lordotic behavior occurred despite the suppression of PR
induction.
These data seem to indicate that EB-induced PR may not
be necessary for the activation of sexual receptivity in
mice. In terms of the level of PR present, Oil + P-treated
mice did not differ from TAM + EB + P treated mice, although
only the latter were capable of lordosis to varying degrees
dependent upon the dose of TAM. Therefore, it seems that
the antagonistic mechanism of TAM is most likely a blockade
of an estrogenic effect other than PR induction.
Species Specific Effects of Tamoxifen
It is clear that the effects of TAM are variable both
within and between species. Differences have been noted in
the way mice and rats respond to TAH. Nhen TAM is
administered alone neither species is sexually receptive.
However, in rats, the dose of TAH (2 mg) that is incapable
of activating lordosis significantly increased PR in the
26
HPOA (Etgen & Shammamian, 1986). In mice, however, a dose
(100 ~g) that did not activate lordosis had no inductive
effects on PR. When TAM (2 mg) was administered
simultaneously with EB, only minimal suppression of PR
induction was exhibited in rats, whereas TAM totally
suppressed EB-induced PR induction in all of the doses
utilized (5-100 ~g) in mice. The fact that data from rats
were obtained with a much higher dose of TAM does not seem
to explain the disparate effects of TAM in the two species.
In addition, the highest dose of TAM used in the present
study (100 ~g) translates to an approximate dose of 3.3mg/kg
body weight. This is close to the 5mg/kg dose which was
utilized in rats to suppress E-dependent responses.
Variability of Tamoxifen Action in Mice
In mice, the biochemical component (PR induction) was
more sensitive to the antagonistic properties of TAM than
the behavioral component (lordosis). Variability of the
action of TAM in the eNS of the mouse is evident when one
compares the effect of TAM on aggression (Simon & Perry,
1988) with the present data on lordosis. Unlike aggression,
where TAM seems to be estrogenic, it was not an agonist for
lordosis and the induction of PR in the HPOA within a
similar dose range. This response specificity may be
attributable to the different neuroanatomical substrates
which regUlate these behaviors; the septum for aggression
(Owen, Peters, & Bronson, 1974; Slotnick & McMullen, 1972)
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and the VMN (ventromedial nucleus) for lordosis (Davis,
McEwen, & Pfaff, 1979; Howard, Etgen & Barfield, 1984). An
additional consideration is that these behaviors are sex-
specific; aggression is male-typical and lordosis is female-
typical.
Potential Mechanisms Mediating the
Variable Action of Tamoxifen
Given the sexual dimorphism in the behavioral systems
discussed above, it becomes possible to speculate that one
source of differences in the eventual response to TAM may be
the different hormonal environments of male and female mice.
A recent report described the effect of perinatal and
pubertal hormonal environments on the differential
availability of the steroid response element (SRE) in
peripheral tissue (Chatterjee & Roy, 1990). The SRE is a
consensus sequence of DNA that the activated receptor
complex binds to regulate gene transcription. The
availability of the SRE may be a function of local chromatin
structure. Tissue specific availability of the SRE due to
the different hormonal environments of the male and female
mouse may play a role in the variability of the effect of
TAM on aggression and lordosis.
Evidence that suggests a possible role of chromatin
organization in hormonal responsiveness necessitates an
understanding of the concept of chromatin acceptor sites.
Chromatin acceptor sites are the nuclear binding sites for
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steroid-receptor complexes. There is much controversy
regarding the identity of the acceptor site. Presently,
three classes of nuclear-.acceptor sites have been
identified, chromatin acceptor sites, the nuclear matrix,
and DNA acceptor sites or SRE (Rories & Spelsberg, 1989).
The chromatin acceptor sites consist of specific chromatin
proteins bound to DNA which bind steroid receptors in a
saturable, high affinity, tissue- and steroid- specific
fashion (Alexander, Greene & Barrack, 1987; Spelsberg,
Littlefield, Seelke, Martin-Dani, & Toyoda, 1983).
The second class, the nuclear matrix (NM), is defined
as the salt- and nuclease- resistant nuclear substructure,
comprised of approximately 7% of the total nuclear protein
and 2% of the total nuclear DNA. The NM is intimately
involved in DNA replication and transcription (Buttyan,
Olsson, Sheard, & Kallos, 1983). The NM contains high
affinity binding sites for both estrogens and androgens
which are diminished following withdrawal of hormonal
stimulation (Barrack & Coffey, 1980). These sites display
saturable, tissue-specific and steroid-specific binding.
Because the NM sites and the chromatin acceptor sites have
many similar properties it is thought that the NM may
represent the active constituent of the chromatin acceptor
sites, and thus represent the same class of acceptor sites
(Barrack, 1987; Hora, Horton, Toft, & Spelsberg, 1986).
The third class of nuclear acceptor sites is the
29
aforementioned SRE, which consists solely of a consensus
sequence of DNA which is specific for each receptor species,
despite a marked similarity between them. For instance, the
SRE for estrogen can be changed into that of glucocorticoids
by changing only two base pairs (Martinez, Givel, & Wahili,
1987) . The SRE is the only DNA element identified as
necessary and sufficient for conferring steroid inducibility
on a gene promoter (Rories & Spelsberg, 1989). However,
there is controversy as to whether the SRE can account for
the biological selectivity of receptor action in vivo, in
light of the similarities between various SREs and the low
degree of binding selectivity observed in in vitro studies.
Binding selectivity is defined as the degree of
discrimination by the activated hormone-receptor between
specific and nonspecific DNA fragments. In light of
reported variable hormonal responsiveness within
circumscribed regions of prostatic tissue (Prins, 1989), it
is difficult to conceive how the SRE, which is presumably
invariant, provides the context for differential regUlation
given that the receptor species are also presumed to be
invariant.
It seems that the most likely candidate for the nuclear
acceptor site is the chromatin acceptor that is comprised of
both the SRE and various nuclear proteins. It has been
suggested that the protein composition of the chromatin may
play a role in the effect of the ligand-receptor complex for
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that specific acceptor site. Support for the role of
chromatin acceptor sites comes from a study in which shark
ER was utilized as a probe to examine chromatin binding in
different shark and mammalian tissue preparations. The only
combination that revealed significant binding was shark
testicular ER with shark testicular chromatin. In addition,
ER from rabbit uterus, shark oviduct or mouse testis bound
minimally to shark testicular chromatin (Ruh, singh, Mak, &
Callard, 1986) indicating that ER-chromatin binding is
tissue- and species-specific. Further support comes from
examining antiestrogen resistance in cell lines. comparison
of the chromatin binding characteristics of antiestrogen-
resistant and -sensitive sublines of MCF-7 cells, subline RR
and E-3 respectively, indicated that resistance is a
function of chromatin composition (Singh, Ruh, Butler & Ruh,
1986) .
Other factors that have been implicated in the variable
response of TAM include domains on the receptor itself as
well as the presence of transcription factors (Green, 1990;
Green & Chambon, 1988; Lees Fawell, & Parker, 1989a, b). ER
contains both constituitive and ligand induced
transcriptional activating functions (TAF1 and TAF2,
respectively; Lees et aI, 1989a,b; Tora, White, Brou,
Tasset, \~ebster, Scheer, & Chambon, 1989). It has been
postulated that the ability of TAN to antagonize E-dependent
processes may stem from its' inability to activate TAF2 (the
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ligand-induced TAF). This may be due to the different
receptor conformations invoked by TAM and E (Ruh, Turner,
Paulson & RUh, 1990). Variable agonist effects have been
ascribed to the differences in the activity of TAF1 in
different tissues and species. For example, removal of TAF2
from the receptor produces a constituitively acting
transcription factor whose activity represents 1-10 % of the
activity seen with the intact human ER or glucocorticoid
receptor (GR) (Hollenberg, Giguere, Segui, & Evans, 1987;
Kumar, Green, Stack, Berry, Jin, & Chambon, 1987). In the
case of the rat GR, though, the activity present represents
50% of the activity of an intact receptor (Godowski,
Rusconi, Miesfeld, & Yamamoto, 1987). The ability of TAF1
to synergize with cell and tissue specific transcription
factors has also been indicated in the variability of
agonist effects. Similar mutants of the human ER (those
that lack TAF2) have approximately 5% intact receptor
activity in HeLa or COS cells (Bocquel, Kumar, Stricker,
Chambon, & Gronemeyer, 1989; Kumar, et al., 1987) but 60-70%
activity in chick embryo fibroblasts and 100% activity in
yeast (Tora, et al., 1989; White, Metzger, & Chambon, 1988).
This variability in TAF1 function in the different cell
lines has been taken as evidence for cell-specific
differences in presence of transcription factors which,
together with the receptor, regulate transcription. Because
lordosis and aggression are regulated by different
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neuroanatomical regions there exists the possibility tbat
such tissue and/or cell specific variation in the presence
of transcription factors may play a role in the variable
effects of TAM in male and female behaviors .
...,...
33
CHAPTER FIVE
FUTURE RESEARCH DIRECTIONS
The preceding discussion makes it evident that complex
biochemical investigations are necessary to elucidate the
molecular mechanisms responsible for the differing actions
of TAM in the male and female mouse CNS. For example,
intact as well as sequentially deproteinized chromatin from
the VMN and the septum of both the female and the male could
be assayed with radiolabell~d TAM to determine the
availability of the SRE in the tissue preparations of the
different sexes. An alternative approach to investigating
the hormonal regUlation of chromatin organization would be
the investigation of another male-typical behavior, such as
mounting, Which is regulated by the medial preoptic area
(MPOA) (Christensen & Clemens, 1975; Lisk, 1967). If TAM
acts as an agonist for mounting this would provide support
for the hypothesis that the availability of SRE for TAM-ER
complex in the mouse CNS may be the result of hormonally
regulated chromatin organization.
34
CHAPTER SIX
SUMMARY
In conclusion, TAM did not possess any agonist
properties in the CNS of the female mouse for the activation
of lordosis or for the induction of PR in the HPOA within
the dosage range utilized. Antagonism was evident in the
ability of TAM to suppress lordosis as a function of dose,
although suppression was never totally complete. However,
all of the doses suppressed PR induction to the basal level
exhibited by oil-treated mice. When these results are
compared to those obtained in a comparable study utilizing
rats (Etgen & Shamammian, 1986), clear differences emerge in
the biochemical data. Concerning PR induction, TAM was an
agonist in rats when administered alone, but when
administered simultaneously with EB, TAM acted not as an
antagonist, but as a weak agonist evident by only minimal
suppression of PR induction.
The effects of TAM vary within mice, dependent upon the
response under consideration. This is evident when
comparing the results of the present study with the effect
of TAM on aggression in intact male mice (Simon & Perry,
1988). TAM potentiated aggression, acting estrogenically,
in intact males, while it was solely an antagonist in the
female for the responses studied. Due to the sexually
dimorphic nature of aggression and lordosis, it was
speculated that the agonist/antagonist action of TAM in the
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mouse eNS may be a result of differential chromatin
organization due to hormonal environment. In light of the
species-, tissue-, and ev~en cell- specific activity of
transcriptional activating functions (TAF's) localized on
ER, it is also plausible that variable TAF activity may also
serve as the mechanism for the agonist/antagonist actions of
TAM.
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